drugset / Trial / NCT00922324

Safety and Tolerability of STP206 in Healthy Adult Subjects

NCT00922324 ↗

Phase 1 Completed 24 enrolled Leadiant Biosciences, Inc.
RandomizedParallel-groupQuadruple-blind

Summary

The study will assess the safety, tolerability and fecal shedding of STP206 when given as a single dose and when given as daily doses for one week.

Timeline

Start
2010-03
Primary completion
2010-06
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject STP206 Other / unclassified — Oral

Indications

No indication recorded.